Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2026-05-22 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an official corporate announcement detailing the 2025 annual equity distribution (profit distribution) plan: cash dividend per 10 shares, total amount, record date, ex-dividend date, dividend recipients and payment method. This aligns exactly with a Notice of Dividend Amount (dividend announcement), not a full financial report or proxy. Therefore, it should be classified as Code DIV.
2026-05-22 Chinese
关于聘任袁春先生为公司联席CEO兼首席商务官的公告
Board/Management Information Classification · 90% confidence The document is an official announcement by the company’s board regarding the appointment of a new senior executive (co-CEO and Chief Commercial Officer). It outlines board resolutions, executive responsibilities, term of office, and credentials of the appointee. This clearly fits the category of Board/Management Information (announcements of changes in senior management).
2026-05-20 Chinese
关于第九届董事会第五次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an official announcement of the company’s 9th Board of Directors 5th meeting resolution, specifically approving the appointment of a senior management executive (Co-CEO and Chief Business Officer). This falls under Board/Management Information.
2026-05-20 Chinese
关于参加深圳证券交易所深研发求精进·积蓄医药成长新动能2025年度集体业绩说明会的公告
Regulatory Filings Classification · 90% confidence The document is a brief announcement by Anhui Anke Bioengineering (Group) Co., Ltd. regarding its participation in the Shenzhen Stock Exchange’s 2025 collective performance explanation meeting. It contains scheduling details and Q&A arrangements, but no substantive financial data, report attachments, or presentation materials. This is an event notice rather than an actual financial report, investor presentation file, or earnings announcement. It therefore falls into the general regulatory announcement category.
2026-05-15 Chinese
关于部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 92% confidence The document is an official corporate announcement detailing the completion of a share repurchase and cancellation of restricted shares under the company’s third restricted stock incentive plan. It specifies the number of shares repurchased, prices, board approvals, and changes in share capital. This clearly falls under a transaction in the company’s own shares (share buyback), matching the “Transaction in Own Shares” category.
2026-05-12 Chinese
关于公司第2期员工持股计划所持公司股票出售完毕的公告
Transaction in Own Shares Classification · 82% confidence The document is a formal corporate announcement detailing the completion of the sale of shares held under the company’s 2nd Employee Shareholding Plan. It does not present financial statements or performance, nor is it an AGM, proxy, earnings release, or regulation report. Instead, it reports the disposal of company shares in the market (through the employee plan). This fits the definition of “Transaction in Own Shares” (POS).
2026-05-10 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.